Marketing for Machines: How AI Gatekeepers Are Reshaping Pharma Content Visibility
A physician asks an AI assistant for the latest treatment insights. Within seconds, the system summarizes clinical evidence, filters trusted sources, and recommends the...
Advisory Committees as Brand Moments: Preparing for Public Scientific Scrutiny
One tense question from an FDA panel member can erase months of carefully managed messaging. A hesitant executive response can trigger investor panic before...
Real-Time Evidence, Real-Time Marketing: Why Static Campaigns Are Becoming a Risk
Pharmaceutical marketing is entering a new era. In 2026, the pace of clinical evidence generation has accelerated so quickly that traditional campaign planning can...
Compounded vs. Branded vs. Generic: The New Battle for Patient Understanding
The 2026 GLP-1 shortage changed more than prescription availability. It changed how patients think about medicine itself. As shortages pushed consumers toward compounded alternatives,...
The Platform Problem: When Telehealth and Retail Own the Pharma Customer Experience
A patient wakes up with symptoms, opens a telehealth app, speaks with a clinician, receives a prescription, and schedules medication delivery within 20 minutes....
Press Releases Are Now Promotional: Why Pharma Comms Needs an MLR Mindset
Pharmaceutical companies once viewed press releases as relatively low-risk communications. Many organizations believed that corporate announcements sat outside the strict rules governing promotional materials....
Policy Is Now a Marketing Variable: How Pharma Marketers Must Adapt to Constant Regulatory...
Pharma policy marketing is no longer a niche concern. Today, it plays a central role in how therapies are positioned, communicated, and ultimately adopted....
Timing Still Wins: What Competitive Drug Launches Teach Pharma Marketers About Market Entry Strategy
What if the most important decision in launching a drug is not what you say, but when you say it? In many therapeutic categories,...
Competing with Misinformation: How Pharma Marketers Can Win in a Fragmented Health Content Landscape
A patient scrolls through their phone and sees three conflicting health claims in less than a minute. One promises a miracle cure, another warns...
When Unofficial Alternatives Shape the Market: What Pharma Marketers Can Learn from Compounded Drugs
The rise of compounded drugs is quietly reshaping the pharmaceutical landscape, and it raises an important question: how should brands respond when competition doesn’t...
